BGLC on Nasdaq
BioNexus Gene Lab Corp
In its 2026 annual report the company says: “BioNexus Gene Lab Corp. is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn.”5 It is headquartered in Kuala Lumpur, Malaysia.2 Its shares trade on Nasdaq under the symbol BGLC.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Psychemedics Corporation, Renalytix plc or AMERICAN SHARED HOSPITAL SERVICES, or pick any stock.
- TickerBGLC on Nasdaq2
- IndustryServices-Medical Laboratories2
- HeadquartersKuala Lumpur, Malaysia2
- Incorporated inWY4
- Business addressUnit A-28-7, Tower A, Menara Uoa Bangsar, No. 5 Jln Bangsar Utama 1, Kuala Lumpur, 590004
- Filer category, Emerging growth company4
- Legal formProfit Corporation2
- LEI549300COYSKRA3Z7E5312
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressC/O Cloud Peak Law Group, P.C., 82801 Sheridan, United States2
- Registered withBusiness Center (Wyoming Secretary of State), 2017-0007535432
See how the biggest companies compare on our leaderboards
BioNexus Gene Lab Corp. is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (“Chemrex”) and MRNA Scientific Sdn. Bhd. (“MRNA Scientific”). Chemrex is engaged in the distribution of chemical raw materials, primarily for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
MYMember brought in 79% of the revenue BioNexus Gene Lab Corp broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| MYMember | $7.5M | $5.8M |
| MV | $762.1K | $681.0K |
| LK | $459.0K | $452.6K |
| SGMember | $572.0K | $240.8K |
| ID | $138.3K | $114.9K |
| BD | $123.3K | $106.3K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue85¢$6.3M
- Research and development1¢$50.7K
- Other costs14¢$1.0M
Out of $7.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| REVENUE (including $68,104 and $112,556 of revenue from related party for the year ended December 31, 2025 and 2024 respectively) | $7.4M | $9.5M |
| COST OF REVENUE (including $9,503 and $297,736 of cost of revenue from related party for the year ended December 31, 2025 and 2024, respectively) | -$6.3M | -$8.2M |
| GROSS PROFIT | $1.1M | $1.3M |
| Dividend income | $22.1K | $68.1K |
| Interest income | $83.9K | $147.6K |
| Fair value gain on investments in equity securities | $0 | $69.5K |
| Gain on disposal of investments in equity securities | $27.2K | $38.4K |
| Reversal of expected credit losses | $144.8K | $1.7M |
| Gain from foreign exchange | $94.7K | $0 |
| Others | $59.5K | $59.4K |
| TOTAL OTHER INCOME | $432.1K | $2.1M |
| Sales and marketing | -$1.7M | -$2.0M |
| Research and development | -$50.7K | -$47.5K |
| General and administrative (including $4,206 and $1,969 of rental expenses to related party for the year ended December 31, 2025 and 2024, respectively) | -$1.5M | -$1.8M |
| Share-based compensation | -$794.8K | -$141.0K |
| Fair value loss on investments in equity securities | -$94.0K | $0 |
| Provision for expected credit losses | -$271.2K | -$883.5K |
| TOTAL OPERATING EXPENSES | -$4.5M | -$4.9M |
| LOSS FROM OPERATIONS | -$3.0M | -$1.6M |
| FINANCE COSTS | -$19.5K | -$21.1K |
| LOSS BEFORE TAXES | -$3.0M | -$1.6M |
| Deferred tax | $0 | -$12.3K |
| Income tax | $0 | $15.8K |
| Tax expense | $0 | $3.5K |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS | -$3.0M | -$1.6M |
| Foreign currency translation gain | $434.3K | $122.3K |
| COMPREHENSIVE LOSS | -$2.6M | -$1.5M |
| Earnings per share - Basic and diluted | -$1.61 | -$0.90 |
| Weighted average number of common stocks outstanding, Basic and Diluted # | 1.9M shares | 1.8M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and bank balances | $2.4M | $1.6M | |
| Fixed deposits placed with financial institutions (including $1,553,322 and $1,490,461 of fixed deposits with original maturities more than 3 months as of December 31, 2025 and December 31, 2024 respectively) | $1.7M | $2.8M | |
| Trade receivables, net of allowance for credit losses of $703,995 and $517,877 as of December 31, 2025 and December 31, 2024 respectively (including $31,420 and $47,272 of trade receivables from related party as of December 31, 2025 and December 31, 2024 respectively) | $505.9K | $1.4M | |
| Other receivables, deposits and prepayments | $81.7K | $203.7K | |
| Other assets | $83.3K | $0 | |
| Tax recoverable | $61.4K | $84.2K | |
| Inventories (including goods in transit of $Nil and $188,797 as of December 31, 2025 and December 31, 2024 respectively) | $676.7K | $1.4M | |
| Total current assets | $5.4M | $7.4M | |
| Operating lease right-of-use assets | $177.7K | $215.2K | $141.5K |
| Property, plant and equipment, net | $1.6M | $1.5M | |
| Investments in equity securities | $2.0M | $1.3M | |
| Total non-current assets | $3.8M | $3.0M | |
| TOTAL ASSETS | $9.3M | $10.4M | |
| Trade payables | $2.3K | $1.5M | |
| Other payables and accrued liabilities | $401.6K | $284.1K | |
| Current portion of operating lease liabilities | $59.1K | $50.8K | |
| Advance payment from customer | $8.4K | $95.9K | |
| Amount owing to directors | $49.5K | $17.2K | |
| Total current liabilities | $521.0K | $2.0M | |
| Non-current portion of operating lease liabilities | $116.9K | $159.7K | |
| Total non-current liability | $116.9K | $159.7K | |
| TOTAL LIABILITIES | $637.9K | $2.1M | |
| As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value; 30,000,000 share authorized and no shares outstanding (on a post-reverse stock split basis)*. | $20.2M | $17.3M | |
| Additional paid in capital | -$5.0M | -$5.0M | |
| Accumulated deficit | -$6.4M | -$3.4M | |
| Accumulated other comprehensive losses | -$120.7K | -$555.0K | |
| TOTAL STOCKHOLDERS' EQUITY | $8.6M | $8.3M | $9.7M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $9.3M | $10.4M | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares outstanding | 2.4M shares | 1.8M shares | |
| Preferred stock, par value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 30.0M shares | 30.0M shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Fixed deposits | $1.6M | $1.5M | |
| Allowances for credit losses in trade receivable | $704.0K | $517.9K | |
| Trade receivables from related parties | $31.4K | $47.3K | |
| Inventories, goods in transit | $0 | $188.8K |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and bank balances | $2.4M | $1.6M | |
| Fixed deposits placed with financial institutions (including $1,553,322 and $1,490,461 of fixed deposits with original maturities more than 3 months as of December 31, 2025 and December 31, 2024 respectively) | $1.7M | $2.8M | |
| Trade receivables, net of allowance for credit losses of $703,995 and $517,877 as of December 31, 2025 and December 31, 2024 respectively (including $31,420 and $47,272 of trade receivables from related party as of December 31, 2025 and December 31, 2024 respectively) | $505.9K | $1.4M | |
| Other receivables, deposits and prepayments | $81.7K | $203.7K | |
| Other assets | $83.3K | $0 | |
| Tax recoverable | $61.4K | $84.2K | |
| Inventories (including goods in transit of $Nil and $188,797 as of December 31, 2025 and December 31, 2024 respectively) | $676.7K | $1.4M | |
| Total current assets | $5.4M | $7.4M | |
| Operating lease right-of-use assets | $177.7K | $215.2K | $141.5K |
| Property, plant and equipment, net | $1.6M | $1.5M | |
| Investments in equity securities | $2.0M | $1.3M | |
| Total non-current assets | $3.8M | $3.0M | |
| TOTAL ASSETS | $9.3M | $10.4M | |
| Trade payables | $2.3K | $1.5M | |
| Other payables and accrued liabilities | $401.6K | $284.1K | |
| Current portion of operating lease liabilities | $59.1K | $50.8K | |
| Advance payment from customer | $8.4K | $95.9K | |
| Amount owing to directors | $49.5K | $17.2K | |
| Total current liabilities | $521.0K | $2.0M | |
| Non-current portion of operating lease liabilities | $116.9K | $159.7K | |
| Total non-current liability | $116.9K | $159.7K | |
| TOTAL LIABILITIES | $637.9K | $2.1M | |
| As at December 31, 2025, common stock, no par value; 300,000,000 shares authorized and 2,417,314 shares outstanding, and preferred stock, no par value; 30,000,000 shares authorized and no shares outstanding. As at December 31, 2024, common stock, no par value; 300,000,000 shares authorized and 1,796,766 shares outstanding, and preferred stock, no par value; 30,000,000 share authorized and no shares outstanding (on a post-reverse stock split basis)*. | $20.2M | $17.3M | |
| Additional paid in capital | -$5.0M | -$5.0M | |
| Accumulated deficit | -$6.4M | -$3.4M | |
| Accumulated other comprehensive losses | -$120.7K | -$555.0K | |
| TOTAL STOCKHOLDERS' EQUITY | $8.6M | $8.3M | $9.7M |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $9.3M | $10.4M | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, shares authorized | 300.0M shares | 300.0M shares | |
| Common stock, shares outstanding | 2.4M shares | 1.8M shares | |
| Preferred stock, par value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 30.0M shares | 30.0M shares | |
| Preferred stock, shares outstanding | 0 shares | 0 shares | |
| Fixed deposits | $1.6M | $1.5M | |
| Allowances for credit losses in trade receivable | $704.0K | $517.9K | |
| Trade receivables from related parties | $31.4K | $47.3K | |
| Inventories, goods in transit | $0 | $188.8K |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$3.0M | -$1.6M |
| Amortization of right-of-use asset | $56.4K | $49.0K |
| Allowances for expected credit losses | $271.2K | $883.5K |
| Recoveries for expected credit losses | -$144.8K | -$1.7M |
| Bad debts written off | $0 | $6.3K |
| Depreciation of property, plant and equipment | $111.9K | $104.2K |
| Dividend income | -$22.1K | -$68.1K |
| Fair value loss/(gain) on investments in equity securities, net | $94.0K | -$69.5K |
| Loss arising from settlement of supplier contract dispute | $0 | $29.5K |
| Gain on disposal of investments in equity securities | -$27.2K | -$38.4K |
| Loss on lease termination | $0 | $1.4K |
| Impairment on property | $0 | $40.2K |
| Share-based compensation | $794.8K | $141.0K |
| Operating loss before working capital changes | -$1.9M | -$2.2M |
| Inventories | $711.9K | -$250.9K |
| Trade, other receivables and other assets | $782.8K | $147.8K |
| Trade and other payables | -$1.4M | $204.3K |
| Advance payment from customer | -$87.5K | $95.9K |
| Operating lease liabilities | -$34.5K | -$42.9K |
| Tax recoverable/(liabilities) | $22.8K | -$38.8K |
| Net cash used in operating activities | -$1.8M | -$2.1M |
| Acquisition of investments in equity securities | -$9.2K | -$492.7K |
| Dividend income | $22.1K | $68.1K |
| Change in fixed deposits placed with original maturities more than three months | -$62.9K | -$78.8K |
| Purchase of plant and equipment | -$37.0K | -$227.0K |
| Proceeds from disposal of investments in equity securities | $1.0M | $1.1M |
| Proceeds from settlement of supplier contract dispute | $0 | $79.9K |
| Net cash generated from investing activities | $944.8K | $418.2K |
| Advances from Directors | $32.3K | $4.0K |
| Cash paid for fractional shares in reverse stock split | -$775 | $0 |
| Share subscription | $267.3K | $0 |
| Net cash generated from financing activities | $298.8K | $4.0K |
| Foreign currency translation adjustment | $194.2K | $40.3K |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | -$400.6K | -$1.6M |
| Fixed deposits placed with financial institutions with original maturities of three months or less | $103.0K | $1.3M |
| Cash and bank balances | $2.4M | $1.6M |
| Cash and cash equivalents, end of financial year | $2.5M | $2.9M |
| Interest paid | -$6.9K | -$9.4K |
| Income tax refunded | $43.7K | $0 |
| Income tax paid | -$14.8K | -$40.4K |
| Acquisition of investment via share exchange | -$1.8M | $0 |
No quarter-by-quarter statement was filed.
Corporate structure
BioNexus Gene Lab Corp sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of BioNexus Gene Lab Corp
- Lee Su-Leng Tan Filed SCHEDULE 13D on BioNexus Gene Lab Corp, latest Aug 14, 2026
- Soo Kow Lai Filed SC 13D on BioNexus Gene Lab Corp, latest Jan 17, 2024
- Chan Chong Wong Filed SC 13G on BioNexus Gene Lab Corp, latest Oct 17, 2023
- BioNexus Gene Lab Corp Kuala Lumpur, Malaysia
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What BioNexus Gene Lab Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $2.5M3 Dec 31, 2025 | $2.5M3 Dec 31, 2024 | +1.5% |
| Accumulated depreciation | $868.8K3 Dec 31, 2025 | $757.0K3 Dec 31, 2024 | +14.8% |
| Property and equipment, net | $1.6M3 Dec 31, 2025 | $1.5M3 Dec 31, 2024 | +5.0% |
| Operating-lease assets (leased space) | $177.7K3 Dec 31, 2025 | $215.2K3 Dec 31, 2024 | −17.4% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $2.5M3 Dec 31, 2025 | $2.9M3 Dec 31, 2024 | −13.9% |
| Stakes in other companies (equity method) | $2.0M3 Dec 31, 2025 | $1.3M3 Dec 31, 2024 | +60.3% |
Inventory
Properties, in its own words
The corporate office for MRNA Scientific is located at Unit A-28-7, Level 28, Tower A, Menara UOA Bangsar, No.5 Jalan Bangsar Utama 1, 59000 Kuala Lumpur, Malaysia. The lease commenced on June 1, 2024 and terminates on May 31, 2027, with option to extend till May 31, 2029. The space consists of 2,206 square feet with an annual rent of approximately $30,190.
We also have two laboratories. One of our laboratories is located at 4th Floor, Wisma Life Care, No. 5, Jalan Kerinchi, Bangsar South, 59200 Kuala Lumpur, Malaysia. The lease commenced on November 1, 2016 and terminates on April 30, 2026. The annual rent is approximately $6,563. The other laboratory is located at Lab 353, University Science Malaysia, George Town, Penang, Malaysia. The lease commenced on December 1, 2017 and terminates on November 30, 2026. The space consists of 1,500 square feet with an annual rent of approximately $32,257.
The rest of Item 2
On July 2, 2012, we purchased a 25,000 sq. ft wholesale distribution center at 4, Jalan CJ 1/6, Kawasan Perusahaan Cheras Jaya, 43200 Cheras, Selangor, Malaysia, and two investment properties for $1,395,210. The two investment properties are listed below.
· · An 1,100 sq ft condominium located at No. B-17-03, Duet Residence, Jalan Kinrara 6, Bandar Kinrara, 47180 Puchong, Selangor, purchased on August 26, 2020;
· · A 2,000 sq ft commercial building located at First floor, No. 2B Pelangi Avenue, Jalan Kelicap 42A/KU1, Klang Bandar, Diraja, 41050 Klang, Selangor purchased on September 21, 2020.
On July 1, 2024, we entered into a lease for Lot 238 and 239, Jalan Villaraya 1/9, Kawasan Industri Villaraya, 43500 Semenyih, Selangor. The lease terminates on June 30, 2026, with an option to extend for one year. The purpose of this lease is to establish a manufacturing facility for a new high-quality color paste production line.
Item 2 of the 10-K filed Apr 14, 2026.5
Leadership
Who has led BioNexus Gene Lab Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
Chief operating officer
- Chief executive officerLee Su-Leng Tan Jul 31, 2026 to now14
- Chief executive officerSook Keng Yeoh Oct 4, 2023 to Oct 4, 202315
- PresidentYee Meng Wong Oct 4, 2023 to Oct 4, 202316
- Chief financial officerSet Fui Chong Jul 31, 2026 to now17
- Chief financial officerWei Li Leong Oct 4, 2023 to Oct 4, 202318
- Chief operating officerTai Tan Liong Oct 4, 2023 to Oct 4, 202319
Board members and other officers (12)
- Board memberAbdul Hamid Muhammad Azrul Bin Jul 31, 2026 to now20
- Board memberJook Yuen Low Jul 31, 2026 to now21
- Board memberLee Su-Leng Tan Jul 31, 2026 to now14
- Board memberBoon Teong Teoh Oct 4, 2023 to Oct 4, 202322
- Board memberChai Ping Lin Oct 4, 2023 to Oct 4, 202323
- Board memberChak Hua Yew Oct 4, 2023 to Oct 4, 202324
- Board memberChee Keong Yap Oct 4, 2023 to now25
- Board memberSook Keng Yeoh Oct 4, 2023 to Oct 4, 202315
- Board memberTai Tan Liong Oct 4, 2023 to Oct 4, 202319
- Board memberTeng Fook Fong Oct 4, 2023 to Oct 4, 202326
- Board memberYeat Min Fong Oct 4, 2023 to Oct 4, 202327
- Board memberYee Meng Wong Oct 4, 2023 to Oct 4, 202316
Former names
- BioNexus Gene Lab CoporationJan 29, 2019 to May 8, 20204
Timeline
- Oct 7, 20268-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure28
- Jul 31, 2026New chief executive Lee Su-Leng Tan becomes CEO14
- Jul 28, 20268-K Other events29
- Jun 5, 20268-K Other events30
- Mar 17, 20268-K Regulation FD disclosure; Other events31
- Feb 23, 20268-K Other events32
- Feb 3, 20268-K Other events33
- Dec 30, 20258-K Shareholder vote34
- Dec 23, 20258-K Other events35
- Dec 2, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure36
- Nov 13, 20258-K Entered a material agreement; Regulation FD disclosure37
- Nov 12, 20258-K Entered a material agreement; Unregistered sale of shares; Regulation FD disclosure38
- Oct 23, 20258-K Regulation FD disclosure39
- Oct 4, 2023New chief executive Sook Keng Yeoh becomes CEO15
Calendar
Coming up
- Nov 13, 2026Reports results for the quarter ending Sep/202640
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
128 filings to the SEC since October 2021: 8 annual reports, 19 quarterly reports, 44 major events, 21 insider forms, 3 large holders, 33 other. The latest 20:
- Oct 7, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13D EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 20264 EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 7, 20263 EDGAR
- Jul 31, 20263 EDGAR
- Jul 31, 20263 EDGAR
- Jul 31, 20263 EDGAR
- Jul 31, 20263 EDGAR
- Jul 31, 20263 EDGAR
- Jul 28, 20268-K EDGAR
- Jun 5, 20268-K EDGAR
- May 15, 202610-Q EDGAR
- Apr 14, 202610-K EDGAR
- Mar 31, 2026NT 10-K EDGAR
- Mar 17, 20268-K EDGAR
The 128 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Lee Su-Leng TanSCHEDULE 13D, 1 filing Aug 14, 202641
- Soo Kow LaiSC 13D, 1 filing Jan 17, 202442
- Chan Chong WongSC 13G, 1 filing Oct 17, 202343
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| UBS Group AG | 101 | $197 | 0.0% | −130 |
| Hrt Financial LP | 14,283 | $27 | 0.0% | New |
| Caitong International Asset Management Co., Ltd | 1 | $2 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How BioNexus Gene Lab Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBioNexus Gene Lab Corp1
- CIK0001737523
- Employer ID (EIN)35-26048305
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inWyoming5
- Fiscal year endsDecember 311
- Industry code (SIC)8071 Services-Medical Laboratories1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressUnit A-28-7, Tower A, Menara Uoa Bangsar, No. 5 Jln Bangsar Utama 1, Kuala Lumpur, Kuala Lumpur 59000, Malaysia1
- Phone1-307-241-68981
- Shares outstanding2,933,442 as of Aug 14, 202613
- Public float$4.8M as of Jun 30, 20255
- AuditorJP CENTURION & PARTNERS PLT, Kuala Lumpur, Malaysia PCAOB ID 6723; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceJan 29, 20191
- Filings156 in all: 8-K (48), 10-Q (23), 3 (16), 10-K (7), 10-Q/A (5), 4 (5), NT 10-K (5), NT 10-Q (5)1
All 28 form types
S-1/A (5), UPLOAD (4), 10-K/A (3), 8-K/A (3), CORRESP (3), DEF 14A (3), DEF 14C (3), PRE 14A (3), EFFECT (2), PRE 14C (2), S-1 (2), 424B4 (1), 8-A12B (1), CERT (1), DEFR14A (1), DEFR14C (1), S-3 (1), SC 13D (1), SC 13G (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Apr 14, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Dec 3, 2025
Latest 8-K (8-K) Oct 7, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, no par value | BGLC | Nasdaq |
From the cover page of the 10-K filed Apr 14, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks BioNexus Gene Lab Corp names in Item 1A of its 10-K filed Apr 14, 2026: 47 risks under these headings, as written.5
- We are an early commercial-stage company and have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
- Our growth (organic and inorganic) may require substantial capital and long-term investments.
- Our net losses may continue in the future.
- Any additional capital we raise may not be available on satisfactory terms and may adversely affect stockholders’ holdings or rights.
- Raising additional capital may lead to dilution of shareholdings by our existing shareholders, restrict our operations, and may further result in fair value loss, adversely affecting our financial results.
- General Business and Industry Risks
- We are unable to predict the duration of future economic conditions.
- Global economic conditions could materially adversely impact demand for our products and services.
- Our risk management programs, processes, or procedures for identifying and addressing risks in MRNA Scientific’s business may not be adequate or effectively applied, and this may adversely impact its businesses.
- We may be adversely impacted by changes in laws and regulations, or in their application.
- Business disruptions could seriously harm our future revenue and financial condition and increase its costs and expenses.
- Our lack of insurance could expose us to significant costs and business disruption.
The other 36 risks
- Fluctuations in foreign currency exchange rates could have a material adverse effect on our financial results.
- Risk Related to MRNA Scientific’s Business and Industry
- Exponential growth in biotechnology.
- MRNA Scientific’s inability to manage growth could harm its business.
- MRNA Scientific’s financial prospects depend substantially upon the successful commercialization of the Company’s services and products in the future, which may fail or experience significant delays.
- The marketing, sale and use of MRNA Scientific’s products and services could result in substantial damages arising from products or service liability or professional liability claims, that exceed MRNA Scientific’s resources.
- MRNA Scientific may face technology transfer challenges and expenses in adding new tests to its portfolio and in expanding its reach into new geographical areas.
- MRNA Scientific’s biomarkers have not undergone clinical trials.
- MRNA Scientific currently receives and expects to continue to receive a significant portion of its revenues from its genomic screening products, and if its efforts to further increase the use and adoption of these products fail, its business will be harmed.
- MRNA Scientific’s success depends on their ability to improve and enhance its current tests and new test candidates, which is complex and costly, and the results are uncertain.
- MRNA Scientific faces challenges from the evolving regulatory environment and increasing public awareness on privacy, personal data protection and cybersecurity. Actual or alleged failure to comply with privacy, cybersecurity and data protection-related laws and regulations could adversely affect MRNA Scientific’s business and reputation.
- MRNA Scientific’s software is highly complex and may contain undetected errors.
- MRNA Scientific’s use of “open source” software could subject its proprietary software to general release, adversely affect its ability to sell its tests and subject the company to possible litigation.
- MRNA Scientific may face competition from other biotechnology competitors and its operating results will suffer if MRNA Scientific fail to compete effectively.
- Cyber breaches, loss of data, and other disruptions could compromise sensitive information related to MRNA Scientific’s business or prevent us from accessing critical information and expose us to liability, which could adversely affect MRNA Scientific’s business and its reputation.
- MRNA Scientific plans to expand its tests and services to multiple countries exposes us to risks associated with doing business outside of Malaysia. The expansion may not be successful, which could limit MRNA Scientific’s ability to grow its revenue, net income, and profitability.
- Risk Related to Chemrex’s Business and Industry
- The chemical raw material industry is cyclical and both recessions and prolonged periods of slow economic growth could have an adverse effect on Chemrex’s business.
- The results of Chemrex’s operations are sensitive to volatility in the cost of raw materials, particularly fibre reinforced plastics.
- Disruptions in the supply of chemicals that we distribute or in the operations of our customers could adversely affect our business.
- We have oral contracts with suppliers and customers, which are generally terminable upon notice, and the termination of our relationships with suppliers and customers contracts could negatively affect our business.
- We may lose customers and suffer damage to our reputation if we are unable to meet customer demand for a particular product.
- We may be exposed to product returns and product liability claims and latent defect liability claims.
- Risks Related to Our Operations
- Our officers and directors may in future have outside business activities. As a result, there may be potential conflicts of interest and negatively impact the amount of time they will be able to dedicate to the company.
- We may not be able to attract and retain key senior management members and research and development personnel.
- We may be unable to protect the company’s intellectual property adequately.
- We may be subject to intellectual property claims, which are extremely costly to defend, could require us to pay significant damages and could limit the company’s ability to use certain technologies in the future.
- Audit Committee investigation may result in material adjustments or restatements.
- Internal control deficiencies may persist despite remediation efforts.
- We may pursue collaborations, in-licensing or out-license arrangements, joint ventures, strategic alliances, partnerships or other strategic investments or arrangements, which may fail to produce anticipated benefits and adversely affect the company’s operations.
- Risks Related to Doing Business in the Southeast Asia Region
- Changes in policies in Malaysia and other Southeast Asian countries could have a significant impact upon the company’s ability to operate profitably in Malaysia and the Southeast Asia region.
- Developments in the social, political, regulatory and economic environment in Malaysia may have a material adverse impact on us.
- You may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in Malaysia against the company or its management based on foreign laws, and the ability of U.S. authorities to bring actions in Malaysia may also be limited.
- We are subject to foreign exchange control policies in Malaysia.
- Volatility in our share price may subject us to securities litigation.
- We may never be able to pay dividends and are unlikely to do so.
- Shareholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities.
- We are a “smaller reporting company,” and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.
Legal proceedings
From time to time, the Company may be involved in claims, disputes, investigations, or legal proceedings arising in the ordinary course of business.
As previously disclosed, the Company has been reviewing certain historical transactions involving former officers of Chemrex Corporation Sdn. Bhd. and related governance and approval matters. That review remains ongoing, and the Company is continuing to assess whether any claims or legal actions should be pursued in connection with those matters.
As of the date of this Annual Report, except for the foregoing review and related matters, the Company is not a party to any material legal proceeding, and, to the Company’s knowledge, no material legal proceeding is pending or threatened against the Company or its subsidiaries that the Company believes would have a material adverse effect on its business, financial condition, or results of operations.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16SEC EDGARYee Meng Wong, President
- 17
- 18
- 19
- 20
- 21SEC EDGARJook Yuen Low, Board member
- 22SEC EDGARBoon Teong Teoh, Board member
- 23SEC EDGARChai Ping Lin, Board member
- 24SEC EDGARChak Hua Yew, Board member
- 25SEC EDGARChee Keong Yap, Board member
- 26SEC EDGARTeng Fook Fong, Board member
- 27SEC EDGARYeat Min Fong, Board member
- 28
- 29SEC EDGAROther events
- 30SEC EDGAROther events
- 31
- 32SEC EDGAROther events
- 33SEC EDGAROther events
- 34SEC EDGARShareholder vote
- 35SEC EDGAROther events
- 36
- 37
- 38
- 39SEC EDGARRegulation FD disclosure
- 40NasdaqNasdaq calendar
- 41
- 42
- 43
- 44